TrichoTest™ | 2024 Utilising SNP Association analysis as a prospective approach for personalising androgenetic alopecia treatment Francès MP, Vila-Vecilla L, Valentina Russo, Polonini HC, de Souza GT Dermatology and Therapy,14, 971–981 This study focuses on correlating the genetic mechanisms of Androgenetic alopecia (AGA) with molecular targets involved in the response to current treatment modalities. An anonymised database including 26,607 patients was subjected to analysis. The study establishes a preliminary association between eight specific SNPs and AGA. These genetic markers offer insights into the variability of therapeutic responses, thus underlining the importance of personalised treatment approaches. Read more SEE PRODUCT
Syrspend SF | 2024 Pharmaceutical compounding in veterinary medicine: suspension of Itraconazole Cabañero-Resta, Gema J., Bárbara Sánchez-Dengra, Alejandro Ruiz-Picazo, Marival Bermejo, Virginia Merino, Isabel Gonzalez-Alvarez, and Marta Gonzalez-Alvarez Pharmaceutics, 16(5), 576 The aim of this work is to develop alternative oral formulations of itraconazole for the treatment of dermatophytosis. The most promising formulation contained hydroxypropyl methylcellulose and β-cyclodextrin. This combination of excipients was capable of dissolving the same concentration as the reference product and delaying the precipitation of itraconazole upon leaving the stomach. Moreover, the intestinal permeability of itraconazole was increased more than two-fold. Read more SEE PRODUCT
TrichoConcept | 2024 Clinical safety profile of TrichoConcept™, a line of cosmetic vehicles for personalized treatment of alopecia Marianni B, Polonini HC, Silva C International Journal of Pharmaceutical Compounding, 28(2), 169-175 Alopecia is a chronic dermatological disorder that affects patients worldwide, with a significant impact on quality of life, self-esteem, and psychological wellbeing. The purpose of this study was to examine the irritation, skin sensitization, photoallergy, and phototoxicity potential of a line of ready-to-use vehicles, TrichoConcept™. The results of this study, it is suggested that the investigated products can be considered safe under the evaluated conditions, and the claims “dermatologically tested”, “clinically tested”, and “nonirritant” can be supported. Read more SEE PRODUCT
TrichoConcept | 2024 Compatibility of Caffeine, Clobetasol, Propionate, Dutasteride, Nicotinamide and Progesterone in TrichoFoam™, a natural vehicle for hair foams Polonini HC, de Sousa PL, Silva Carolina CV, Marianni B International Journal of Pharmaceutical Compounding, 28(2), 161-168 Alopecia is a chronic dermatological disorder affecting men and women worldwide. The purpose of this study was to assess topical foams’ physicochemical and microbiological stabilities of formulations compounded with TrichoFoam™ as the ready-touse vehicle. For the conclusion the stability of the active pharmaceutical ingredients from different pharmacological classes with TrichoFoam™, suggesting that this vehicle can be an excellent alternative for personalized alopecia treatment. Read more SEE PRODUCT
InvoMatic | 2023 Development of an immediate release excipient composition for 3D printing via direct powder extrusion in a hospital Rosch M, Gutowski T, Baehr M, Eggert J, Gottfried K, Gundler C, Nürnberg S, Langebrake C, Dadkhah A International Journal of Pharmaceutics, 643, 123218 The goal of the study was to present a possible option for the implementation of 3D-printed tablets into the digital Closed Loop Medication Management system; the required tablet formulation and development of the manufacturing process, as well as the pharmaceutical validation, were conducted. As a result, the developed method is suitable for the implementation of Closed-Loop Medication Management systems in hospital pharmacies and could, therefore, contribute to medication safety. Read more
Syrspend SF | 2023 Compatibility of commonly used active pharmaceutical ingredients in a ready-to-use oral suspending vehicle Mansourian M, Dijkers E, Silva CV, Polonini HC Pharmaceutics, 15(10), 2388 The present study evaluated the stability of amoxicillin trihydrate (50 mg/mL), clozapine (25 mg/mL), indomethacin (5.0 mg/mL), levodopa/carbidopa (10.0/2.5 mg/mL), levothyroxine sodium (T4, 25 µg/mL), lomustine (4.0 and 10.0 mg/mL), methyldopa (25 mg/mL) and procarbazine (10.0 mg/mL) in SyrSpend® SF PH4. The study demonstrated promising stability for the compounded suspensions, as all APIs exhibited stability throughout the study duration and met content uniformity criteria. Read more SEE PRODUCT
Syrspend SF | 2023 Analytical method and stability study for oral suspension of Idebenone in Syrspend® Porru E, Piro F, Comito R, Mosendz A, Minniti E, Conti M, Stancari A, Violante FS Separations, 10(9), 517 Stability studies are essential to know the effect of storage conditions of a galenic product. For the first time, a stability-indicating LC-MS method has been developed to define the stability of IDB suspensions in SyrSpend® Sugar-Free Unflavored (Fagron), a carrier phase formulated for setting up suspensions of active pharmaceutical ingredients (APIs) insoluble or poorly insoluble in water and compatible with it. The proposed method was validated for linearity, accuracy, specificity, robustness, matrix effect and recovery, limit of detection (LOD), limit of quantification (LOQ), and repeatability. Read more SEE PRODUCT
TrichoConcept | 2023 Compounded hair solutions and foams containing minoxidil: Does the color change impact stability? Polonini HC, Silva CV Scientia Pharmaceutica, 91(3), 39 This study aimed to assess the physical–chemical, and microbiological stability and investigate the color change of compounded minoxidil formulations in TrichoSolTM or TrichoFoamTM. HPLC analyses and antimicrobial effectiveness testing were conducted in concentrations from 1.0% to 7.0% of minoxidil. The color change was noticeable, but no other quality attribute was affected. No precipitation was observed, and the pH was relatively stable. Read more SEE PRODUCT
Syrspend SF | 2023 Tacrolimus in solution as an option to inflammatory conditions of the scalp Scharf C, Licata G, Briatico G, Pellerone S, Argenziano G, Giorgio CM Dermatology Practical and Conceptual, 13(2) This study presented a case series where topical tacrolimus was used in a solution vehicle for these conditions. The study included 13 patients, after 1 month, 14 patients (63.6%) had a good response and 7 (31.8%) had excellent response. After 2 months, 16 patients (72.7%) had excellent response, and this response was persistent after 6 months of treatment. Tacrolimus in solution, even if not yet commercially available, was an effective and well tolerated alternative for the maintenance treatment of inflammatory conditions of the scalp. Read more SEE PRODUCT
Biosil® | 2023 Choline-Stabilized Orthosilicic Acid, applications of an oral supplement in dermatology Gaviglio MR, Calomme MR Journal of Plastic and Pathology Dermatology, 19 (1), 17-29 Several clinical trials have investigated the use of choline-stabilized orthosilicic acid as an oral supplement to improve the quality of skin, hair and nails. The present article discusses the potential use of ch-OSA® as an oral supplement in dermatology, its mechanisms of action and other health benefits outside the field of dermatology. For the conclusion, the intake of the choline containing ch-OSA® complex, contributes to a healthy homocysteine metabolism and protects collagen against homocysteine mediated denaturation. Read more